If not accounted for, the unintended inhibition of CYP3A5 and other CYPs can have drastic effects. "When a nonselective CYP3A inhibitor is used to maintain the efficacy of a CYP3A4-metabolized drug, ...

CYP3A4 inhibitors are commonly co-administered to reduce CYP3A4’s effect. This includes ritonavir, which is combined with nirmatrelvir in Paxlovid for mild COVID-19 treatment. However, such CYP3A4 ...

"When a nonselective CYP3A inhibitor is used to maintain the efficacy of a CYP3A4-metabolized drug, the unnecessary inhibition of other CYPs will lead to dangerously elevated plasma levels of ...

The presentation highlighted tolebrutinib’s potential as the first Bruton’s tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the Clinical ...

Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF).

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

Shanghai Frontiers Science Center for Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China State Key Laboratory of ...

Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that ...

SAN DIEGO, CA, USA & BERLIN, Germany I April 03, 2025 I Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, ...